Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 10
Submit an article Journal homepage
48
Views
9
CrossRef citations to date
0
Altmetric
Research Article

New Vessel Formation and Aberrant VEGF/VEGFR Signaling in Acute Leukemia: Does it Matter?

E.S.J.M. de Bont Division of Pediatric Oncology, Department of Pediatrics, Beatrix Children's Hospital, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
,
V.M.E. Neefjes Department of Pathology, Beatrix Children's Hospital, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
,
S. Rosati Department of Hematology, Beatrix Children's Hospital, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
,
E. Vellenga Division of Pediatric Oncology, Department of Pediatrics, Beatrix Children's Hospital, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
&
W.A. Kamps Department of Pathology, Beatrix Children's Hospital, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
Pages 1901-1909 | Published online: 03 Aug 2009

  • Sieff, C.A. and Nathan, D. A. (1994) "The anatomy and physiology of hematopoiesis". In: Nathan and Oski. eds, Hematology of infancy and childhood (WB Saunders Company, Philadelphia).
  • [Line 37]Schrappe, M., Camitta, B., Pui, C.H., Eden, T., Gaynon, P., Gustafsson, G., Janka-Schaub, G.E., Kamps, W., Maseru, G., Sallan, S., Tsuchida, M. and Vilmer, E. (2000) "Long-term results of large prospective trials in childhood acute lymphoblastic leukemia", Leukemia 14, 2193-2194.
  • [Line 76]Stock, W., Tsai, T. Golden, C., Rankin, C., Sher, D., Slovak, M.L., Pallavicini, M.G., Radich, J.R. and Boldt, D.H. (2000) "Cell cycle regulatory gene abnormalities are important determinants of leukcmogenesis and disease biology in adult acute lymphoblastic leukemia". Blood 95, 2364-2371.
  • [Line 112]Stevens, R.F., Hann, I.M., Wheatley, K. and Gray, R.G. (1998) "Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia; results of the United Kingdom Medical Research Council's 10th AMI. trial. MRC Childhood Leukaemia Working Party", Br. J. Haematol. 101, 130-140.
  • [Line 143]Creutzig, U., Zimmermann, M., Ritter, J., Henzt, G., Graf, N., Loffler, H. and Schellong, G. (1999) "Definition of a standard-risk group in children with AMI.", Br. J. Haematol. 104, 630-639.
  • [Line 177]Woods, W.G., Neudorf, S., Gold, S., Sanders, J., Buckley, J.D., Barnard, D.R., Dusenbery, K., DeSwarte, J., Arthur, D.C., Lange, B.J. and Kobrinsky, N.L. (2001) "A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission". Blood 97, 56-62.
  • [Line 215]Folkman, J. (1971) "Tumor angiogenesis: therapeutic implications", N. Engl. J. Med. 285, 1182-1186.
  • [Line 243]Risau, W. (1997) "Mechanisms of angiogenesis", Nature 386, 671-674.
  • [Line 271]Kolkman, J. and Klagsbrun, M. (1987) "Angiogenic factors". Science 235, 442-447.
  • [Line 300]Mignatti, P. and Rifkin, D.B. (1993) "Biology and biochemistry of proteinases in tumor invasion", Physiol. Rev. 73, 161-195
  • [Line 329]Hanahan, D. and Folkman, J. (1996) "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis", Cell 86, 353-364.
  • [Line 358]Maisonpierre, P.C., Sun, C., Jones, P.E. Bartunkova, S., Wiegand, S.J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N., DaIy, T.J., Davis, S., Sato, T.N. and Yancopoulos, G.D. (1997) "Angiopoietin-2. a natural antagonist for Tie2 that disrupts in vivo angiogenesis [see comments]", Science 277, 55-60.
  • [Line 399]Holash, J., Maisonpierre, P.C., Compton, D. Boland, P., Alexander, C.R., Zagzag, D., Yancopoulos, G.D. and Wiegand, S.J. (1999) "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF'. Science 284, 1994-1998.
  • [Line 434]Stratmann, A., Risau, W. and Plate, K.H. (1998) "Cell typespecific expression of angiopoiethin-1 and angiopoiethin-2 suggests a role in glioblastoma angiogenesis [see comments]", Am. J. Pathol. 153, 1459-1466.
  • [Line 464]Asahara, T., Chen, D., Takahashi, T., Fujikawa, K., Keamey, M., Magner, M., Yancopoulos, G.D. and Isner, J.M. (1998) "Tie2 receptor ligands. angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization [see comments]". Circ. Res. 83, 233-240.
  • [Line 499]Asahara, T., Murohara, T., Sullivan, A., Silver, M., Van, d.Z., Li, T., Witzenbichler, B., Schatteman, G. and Isner, J.M. (1997) "Isolation of putative progenitor endothelial cells for angiogenesis". Science 275, 964-967.
  • [Line 535]Shi, Q., Rafii. S., Wu, M.H., Wijelath, E.S., Yu, C., Ishida, A., Fujita, Y. Kothari, S., Mohle, R., Sauvage, L.R., Moore, M.A., Start, R.F. and Hammond, W.P (1998) "Evidence for circulating bone marrow-derived endothelial cells", Blood 92, 362-367.
  • [Line 575]Peichev, M., Naiyer, A.J., Pereira, D., Zhu, Z., Lane, W.J., Willams, M., Oz, M.C., Hicklin, D.J., Wille, L., Moore, M.A.S. and Rafii, S. (2000) "Expression of VEGFR-2 and AC133 by circulating human CD344" cells identifies a population of functional endothelial precursors". Blood 95, 932-958.
  • [Line 613]de Bont, E.S.J.M., Guikema, J.E.J., Scherpen, F., Meeuwsen, T., Kamps, W.A., Vellenga, E. and Bos, N.A. (2001) "Mobilized human CD34 - hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma'', Cancer Res. 61, 7654-7659.
  • [Line 647]Keller, G., Lacaud, G. and Robertson, S. (1999) "Development of the hematopoietic system in the mouse", Exp. Hematol. 27, 777-787.
  • [Line 677]Takuhashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Keamey, M., Magner, M., Isner, J.M. and Asahara, T. (1999) "Ischemia- and cytokine-induced mobilization of bone-marrow-derived endothelial progenitor cells for neovascularization", Nat. Med. 5, 434-438.
  • [Line 713]Asahara, T., Takahashi, T., Masuda, H., Chen, D., Iwaguro, H., Inati, Y., Silver, M. and Isner, J.M. (1999) "VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells", EMBO J. 18, 3964-3972.
  • [Line 748]Bhattacharya, V., McSweeney, P.A., Shi, Q., Bruno, B., lshida, A., Nash, R., Storb, R.F., Sauvage, L.R., Hammond, W.P. and Wu, M.H. (2000) "Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(*) bone marrow cells". Blood 95, 581-585
  • [Line 785]Shalaby, F., Ho, J., Stanford, W.L., Fischer, K.D., Schuh, A.C., Schwartz, L., Bernstein, A. and Rossant, J. (1997) "A requirement for FIkI in primitive and definitive hematopoiesis and vasculogenesis", CeIl 89, 981-990.
  • [Line 820]Gehling, U.M., Ergun. S., Schumacher, U., Wagener, C., Pantel, K., Otte, M., Schuch, G., Schafhausen, P. Mende, T., Kilie, N., Kluge, K., Schafer, B., Hossfeld, D.K. and Fiedler, W. (2000) "In vitro differentiation of endothelial cells from AC133-positive progenitor cells". Blood 95, 3106-3112.
  • Folkman, J. (1995) 'Tumor angiogenesis", In: Mendelsohn, J., Howley, P.M., Israel, M.A. and Liotta, L.A., eds. The Molecular Basis of Cancer (W.B. Saunders Co., Philadelphia), pp 206-232.
  • [Line 896]Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. and Ferrara, N. (1989) "Cascular endothelial growth factor is a secreted angiogenic mitogen", Science 246, 1306.
  • [Line 926]Bellamy, W.T., Richter, L., Frutiger, Y. and Grogan, T.M. (1999) "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies". Cancer Res. 59, 728-733.
  • [Line 957]Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J.C. and Abraham, J.A (1991) "The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing". J. Biol. Chem. 266, 11947-11954.
  • [Line 991]Houck, K.A., Ferrara, N., Winer, J., Cachianes, G. Li, B. and Leung, D.W. (1991) "The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA", Mol. Endocrinol. 5, 1806-1814.
  • [Line 1024]Terman, B.I., Carrion, M.K., Kovacs, E., Rasmussen, B.A., Eddy, R.L. and Shows, T.B. (1991) "Identification of a new endothelial cell growth factor receptor tyrosine kinase". Oncogene 6, 1677-1683.
  • [Line 1057]Tennan, B.I., Dougher-Vermazen, M., Carrion, M.E., Dimitrov, D., Armellino, U.C., Gospodarowicz, D. and Bohlen, P. (1992) "Identification of the KDR tyrosinc kinase as a receptor for vascular endothelial cell growth factor", Biochem. Biophys Res. Commun. 187, 1579-1586.
  • [Line 1091]Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.F. Breitman, M.L. and Schuh, A.C. (1995) "Failure of blood-island formation and vasculogenesis in FIk I deficient mice", Nature 376, 62-66.
  • [Line 1125]Wattenberg, U.W., Coccia, J.B. and Galbraith, A.R. (1994) "Inhibition of carcinogen-induced pulmonary and mammary carcinogenesis by chalcone administered subsequent to carcinogen exposure". Cancer Lett. 83, 165-169.
  • [Line 1155]Kroll, J. and Waltenberger, J. (1997) "The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells", J. Biol. Chem 272, 32521-32527.
  • [Line 1184]Keyt, B.A., Nguyen, H.V., Berleau, L.T., Duane, C.M., Park, J. Chen, H. and Ferrara, V. (1996) "Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis", J. Biol. Chem. 271, 5638-5646.
  • Bematchez, P.N., Soker, S. and Sirois, M., (1999) "Vascular endothelial growth factor effect on endothelial cell proliferation. migration, and platelet-activating factor synthesis is FIk-I-dependenl". J Biol. Chem. 274, 31047-31054.
  • [Line 1244]Shen, H., Clauss, M., Ryan, L. Schmidt, A.M., Tijburg, P., Borden, L., Connolly, D., Stern, D. and Kao, J. (1993) "Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes". Blood 81, 2767-2773.
  • [Line 1280]Kanrio, S., Oda, N., Abe, M., Terai, Y., lto, M., Shitara, K., Tabayashi, K., Shibuya, M. and Sato, Y (2000) "Roles of two VEGF receptors. Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells". Oncogene 19, 2138-2146.
  • [Line 1316]Olofsson, B., Pajusola, K., Kaipainen, A., von, E.G., Joukov, V., Saksela, O., Orpana, A., Pattersson, R.F., Alitalo, K. and Eriksson, U. (1996) "Vascular endothelial growth factor B, a novel growth factor for endothelial cells". Prof. Natl Acad. Sci. USA 93, 2576-2581.
  • [Line 1353]Skobe, M., Hawighorst, T., Jackson, D.G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K. and Detmar, M. (2001) "Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis". Nat. Med. 7, 192-198.
  • [Line 1390]Joukov, V. Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, K., Saksela, O., Kalkkinen, N. and Alitalo, K. (1996) "A novel vascular endothelial growth factor. VCGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR 2) receptor tyrosine kinases". EMBO J. 15, 1751.
  • [Line 1424]Hamada, K., Oike, Y., Takakura, N., Ito, Y., Jussila, L., Dumont, D.J., Alitalo, K. and Suda, T. (2000) "VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis", Blood 96, 3793-3800
  • [Line 1459]Fiedler, W. Graeven, U., Ergun, S., Veragco, S., Kilie, N., Stockschlader, M. and Hossfeld, D.K. (1907) "Vascular endo thelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia", Blood 89, 1870-1875.
  • [Line 1493]Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadbum, A., Hyjek, F., Gill, M., Hicklin, D.J., Witte, L., Moore, M.A. and Rani, S. (2000) "Autocrine simulation of VEGFR-2 activates human leukemic cell growth and migration". J. Clin. Investig. 106, 511-521.
  • [Line 1534]Asahara, T., Bauters, C., Zheng, L.P., Takeshita, S., Burning, S., Ferrara, N., Symes, J.F. and Isner, J.M. (1995) "Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiognesis in vivo". Circulation 92,11365-11371.
  • [Line 1569]Czubayko, F., Liaudef-Coopman, K.D., Aigner, A., Tuveson, A.O., Berchem, G.J. and Wellstein, A. (1997) "A secreted FGF-binding protein can serve as the angiogenic switch in human cancer [see comments]", Nat. Med. 3, 1137-1140.
  • [Line 1602]Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T. and Kozai, Y. (1991) "Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor". Cancer Res. 51, 6180-6184.
  • [Line 1636]Asahara, T., Bauters, C., Pastore, C., Kearney, M., Rossow, S., Bunting, S., Ferrara, N., Symes, J.F. and Isner, J.M. (1995) "Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimai hyperplasia in balloon-injured rat carotid artery". Circulation 91, 2793-2801.
  • [Line 1672]Terui, Y. Ikeda, M., Tomizuka, H., Kasahara, T., Ohtsuki, T., Uwai, M., Mori, M. Itoh, T., Tanaka, M., Yamada, M., Shimamura, S., Ishizaka, Y. Ikeda, K., Ozawa, K., Miura, Y. and Hatake, K. (1998) "Activated endothelial cells induce apoptosis in leukemic cells by endothelial interleukin-8", Blood. 2672-2680.
  • [Line 1714]Koch, A.E., Polverini, H.J., Kunkel, S.L., Harlow, L.A., DiPietro, L.A., Einer, V.M., Einer, S.G. and Strieter, R.M. (1992) "Interleukin-8 as a macrophage-derived mediator of angiogene-sis". Science 258, 1798-1801.
  • [Line 1749]Di Celle, P.F., Carbone, A., Marchis, D., Zhou, D., Sozzani, S., Zupo, S., Pini, M., Mantovani, A. and Foa, R. (1994) "Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active II.-8 protein". Blood 84, 220-228.
  • [Line 1785]Tobler, A., Moser, B., Dewald, B., Geiser, T. Studer, H., Baggiolini, M. and Fey, M.F. (1993) "Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia". Blood 82, 2517-2525.
  • [Line 1819]de Dont, E.S.J.M., Rosati, S., Jacobs, S., Kamps, W.A. and Vellenga, H. (2001) "Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor". Br. J. Haematol. 113, 296-304.
  • [Line 1851]de Boni, E.S.J.M., Vellenga, E., Molema, O., Van Wering, E., De Leij, L.H.F.M., Kamps, W.A (2001) "A possible role for spontaneous Interleukin-8 production by acute myeioid leukemic cells in angiogenesis related processes: work in progress". Med. Pediatr. Oncol 37, 511-517.
  • [Line 1884]Ries, C., Loher, F., Zang, C., Ismair, M.G. and Petrides, P.E. (1999) "Matrix metalloproteinase production by bone marrow mono nuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes". Clin. Cancer Res. 5, 1115-1124.
  • [Line 1916]Janowska-Wieczorek, A., Marquez, L.A., Matsuzaki, A., Hashmi, H.R., Larratt, L.M., Boshkov, L.M., Turner, A.R., Zhang, M.C., Edwards, D.R. and Kossakowska, A.B. (1999) "Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells". Br. J. Haematol 105, 402-411.
  • [Line 1953]Janowska-Wieczorek, A., Marquez, L.A., Nabholtz, J.M., Cabuhat, M.L., Montano, J., Chang, H., Rozmus, J., Russell, J.A., Edwards, D.R. and Turner, A.R. (1999) "Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(-) cells and their transmigration through reconstituted basement membrane". Blood 93, 3379-3390.
  • [Line 1990]Borregaard, N. and Cowland, J.B. (1997) "Granules of the human neutrophilic polymorphonuclear leukocyte". Blood 89, 3503-3521.
  • [Line 2019]Fibbe, W.E., Pruijt, J.F., Velders, G.A., Opdenakker, C., van, K.Y., Higdor, C.G. and Willentze, R. (1999) "Biology of IL-8-induced stem cell mobilization". Ann. NY Acad. Sci. 872 (71-82), 71-82.
  • [Line 2054]Kossakowska, A.E., Edwards, D.R. Prusinkiewicz, C., Zhang, M.C., Guo, D., Urbanski, S.J., Grogan, T., Marquez, L.A. and Janowska-Wieczorek, A. (1999) "Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-I) expression in malignant non-Hodgkin's lymphomas", Blood 94, 2080-2089.
  • [Line 2090]Esparza, J., Vilardell, C., Calvo, J., Juao, M., Vives, J., Urbano-Marquez, A., Yague, J. and Cid, M.C. (1999) "Fibtonectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MTl-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways". Blood 94, 2754-2766.
  • [Line 2125]Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E. and Folkman, J. (1997) "Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia". Am. J. Partial. 150, 815-821.
  • [Line 2158]Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. and Dammacco, F. (1999) "Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma". Blood 93, 3064-3073.
  • [Line 2194]Padro, T., Ruiz, S., Bicker, R., Burger, H., Steins, M., Kienast, J., Buchner, T. Berdel, W.E., Mesters, K.M., Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R.M., Serve, H., Berdel, W.E. and Kienast, J. (2000) "Increased angiogenesis in the bone marrow of patient's with acute myeloid leukemia. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma". Blood 95, 2637-2644.
  • [Line 2239]Hussong, J.W., Rodgers, G.M. and Shami, P.J. (2000) "Evidence of increased angiogenesis in patients with acute myeloid leukemia". Blood 95, 309-314.
  • [Line 2269]Aguayo, A., Estey, L., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., Giles, E. Estrov, Z., Barlogie, B. and Albitar, M. (1999) "Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia". Blood 94, 3717-3721.
  • [Line 2306]Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilie, N., Stockschlader, M. and Hossfeld, D.K. (1997) "Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia", Blood 89, 1870-1875.
  • [Line 2340]Kuittinen, O., Savolainen, E.R., Koistinen, P. and TurpeenniemiHujanen, T. (1999) "Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML", Anticancer Res. 19, 4395 4400.
  • [Line 2371]de Bont, E.S.J.M., Fidler, V., Meeuwsen-de Boer, G.J., Scherpen, F., Hählen, K. and Kamps, W.A. (2001) "VEGF secretion is an independent prognostic factor for relapse-free survival in pediatric AMI. patients". Clin. Cancer Res.
  • [Line 2398]Aguayo, A., Kantarjian, H., Mansbouri, T., Gidel, C., Estey, E., Thomas, D., Koller, C., Estrov, Z., O'Brien, S., Keating, M., Freireich, R. and AIbitar, M. (2000) "Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes". Blood 96, 2240-2245.
  • [Line 2437]Aguayo, A., O'Brien, S., Keating, M., Manshouri, T., Gidel, C., Barlogie, B., Beran, M., Koller, C., Kantarjian, H. and AIbitar, M. (2000) "Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia". Blood 96, 768-770.
  • [Line 2474]Kuittinen, O., Savolainen, E.R., Koistinen, P., Mottonen, M. and Turpeenniemi-Hujanen, T. (2001) "MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL)". Leukemia Res. 25, 125-131.
  • [Line 2506]Vellenga, E., Young, D.C., Wagner, K., Wiper, D., Ostapovicz, D. and Griffin, J.D. (1987) "The effects of OM-CSF and G-CSF in promoting growth of clonogenic cells in acute mycloblastic leukemia". Blood 69, 1771-1776.
  • [Line 2539]Griffin, J.D., Rambaldi, A., Vellenga, E., Young, D.C., Ostapovicz, D. and Cannistra, S.A. (1987) "Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors". Blood 70, 1218-1221.
  • [Line 2572]Dokter, W.H., Tuyi, L., Sierdsema, S.J., Esselink, M.T. and Vellenga, F. (1995) "The spontaneous expression of interleukin-l beta and interleukin-6 is associated with spontaneous expression of AP-I and NF-kappa B transcription factor in acute myeloblastic leukemia cells". Leukemia 9, 425-432.
  • [Line 2604]Ratajczak, M.Z., Ratajczak, J., Machalinski, B., Majka, M., Marliez, W., Carter, A., Pietrzkowski, Z. and Gewirtz, A.M. (1998) "Role of vascular endothelial growth factor (VEGF) and placentaderived growth factor (PIGF) in regulating human haemopoietic cell growth", Br. J. Haematol. 103, 969-979.
  • Dias, S., Hattori, K., Heissig, B., Zhu, Z., Wu, Y., Witte, L., Hicklin, D.J., Tateno, M., Bohlen, P., Moore, M.A. and Rafii, S. (2001) "Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human luekemias". Proc. Natl Acad. Sci. USA 98, 10857-10862.
  • [Line 2677]Tallquist, M.D., Soriano, H. and Klinghoffer, R.A. (1999) "Growth factor signaling pathways in vascular development", Oncogene 18, 7917-7932.
  • [Line 2707]Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T. and Kerbel, R.S. (1995) "Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis". Cancer Res. 55, 4575-4580.
  • [Line 2741]Milanini, J., Vinals, F., Pouyssegur, J. and Pages, G. (1998) "p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts". J Biol. Chem. 273, 18165-18172.
  • Arbiser, J.L., Moses, M.A., Fernandez, C.A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H.R. and Folkman, J. (1997) "Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways", Proc. Natl Acad Sci. USA 94, 861-866.
  • Jiang, B.H., Zheng, J.Z., Aoki, M. and Vogt, P.K. (2000) "Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells". Proc. Natl Acad. Sci. USA 97, 1749-1753.
  • [Line 2842]Turkson, J., Bowman, T., Adnane, J., Zhang, Y., Djeu, J.Y., Sekharam, M., Frank, D.A., Holzman, L.B., Wu, J., Sebti, S. and Jove, R. (1999) "Requirement for Ras/Rac1-mediated p38 and cJun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Sre oncoprotein". MoI. Cell. Biol. 19, 7519-7528.
  • [Line 2880]Mukhopadhyay, D., Tsiokas, L. and Sukhatme, V.P. (1995) "Wildtype p53 and v-Src exert opposing influences on human vascular endothclial growth factor gene expression". Cancer Res. 55, 6161-6165.
  • [Line 2910]Tau, Z., Guo, C., Nagaich, A.K., Connell, T., Sajto, S., Moul, J.W., Seth, P., Appella, E. and Srivastava, S. (2000) "p53 Regulates the expression of the tumor suppressor gene maspin". J. Biol Chem. 275, 6051-6054.
  • [Line 2946]Zhang, M., Volpert, O., Shi, Y.H. and Bouck, N. (2000) "Maspin is an angiogenesis inhibitor", Nat. Med. 6, 196-199.
  • [Line 2977]Pages, G., Berra, R., Milanini, J., Levy, A.P. and Pouyssegur, J. (2000) "Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability". J Biol. Chem. 275, 2648-2649).
  • [Line 3009]Bynie, J.L., Carter, G.I., Davies, J.M., Haynes, A.P., Russell, N.H. and Cross, N.C. (1998) "A novel BCR-ABL fusion gene (e2/1 a) in a patient with Philadelphia positive chronic myelogenous leukaemia and un aggressive clinical course". Br. J. Haematol. 103, 791-794.
  • [Line 3042]Radich, J.P., Kopecky, K.J., Willman, C.L., Weick, J., Head, D., Appelbaum, F. and Collins, S.J. (1990) "N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance". Blood 76, 801-807.
  • [Line 3076]Weijzen, S., Velders, M.P. and Kast, W.M. (1999) "Modulation of the immune response and tumor growth by activated Ras". Leukemia 13, 502-513.
  • [Line 3106]Kappel, A., Schlaeger, T.M., Flamme, I., Orkin, S.H., Risau, W. and Breier, G. (2000) "Role of SCL/Tal-1. GATA, and ets transcription factor binding sites for the regulation of flk-l expression during murine vascular development". Blood 96, 3078-3085.
  • [Line 3139]Labastie, M.C., Cortes, F., Romeo, P.H., Dulac, C. and Peault, B. (1998) "Molecular identity of hematopoietic precursor cells emerging in the human embryo", Blood 92, 3624-3635.
  • [Line 3171]Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., Bohlen, P. and Kerbel, R.S. (2000) "Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without over loxicity [see comments]". J. Clin. Investig. 105, R15-R24.
  • [Line 3206]Mauceri, H.J., Hanna, N.N., Beckett, M.A., Gorski, D.H., Staba, M.J., Stellato, K.A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G.A., Sukhatme, V.P., Kufe, D.W. and Weichselbaum, R.R. (1998) "Combined effects of angiostatin and ionizing radiation in antitumor therapy". Nature 394, 287-291.
  • [Line 3247]Browder, T. Butterfield, C.E., Kraling, B.M., Shi, B., Marshall, B., O'Reilly, M.S. and Folkman, J. (2000) "Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer". Cancer Res. 60, 1878-1886.
  • [Line 3281]Folkman, J. (1992) 'The role of angiogenesis in tumor growth". Semin. Cancer Biol. 3, 65-71.
  • [Line 3309]Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S. and Herrara, N. (1993) "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo". Nature 362, 841-844.
  • [Line 3343]Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S. and Kusenig, N.B. (1997) "Halting angiogenesis suppresses carcinoma cell invasion". Nat. Med. 3, 1222-1227.
  • [Line 3375]Millauer, B., Shawver, L.K., Plate, K.H., Risau, W. and Ullrich, A. (1994) "Glioblastoma growth inhibited in vivo by a dominant-negative FIk-I mutant". Nature 367, 576-579.
  • [Line 3407]Millauer, B., Longhi, M.P., Plate, K.H., Shawver, L.K., Risau, W., Ullrich, A. and Strawn, L.M. (1996) "Dominant-negative inhibition of PIk-1 suppresses the growth of many tumor types in viva". Cancer Res. 56, 1615-1620.
  • [Line 3441]Masood, R., Cai, J., Zheng, T., Smith, D.L., Hinton, D.R. and Gill, P.S. (2001) "Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors". Blood 98, 1904-1913.
  • [Line 3474]Mesters, R.M., Padro, T., Bieker, R., Steins, M., Kreuter, M., Goner, M., Kelsey, S., Seigalla, P., Kiedler, W., Buchner, T. and Berdel, W.E. (2001) "Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia". Blood 98, 241-243.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.